FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:740-741 August 17, 2006 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Tumor necrosis factor antagonists have been shown to be effective agents in the treatment of rheumatoid arthritis; however, they have also been shown to increase the risk of the reactivation of tuberculosis in patients with latent infection^1,2 and may render the tuberculosis refractory to drug therapy.^3,4 Decisions regarding the treatment of patients with refractory rheumatoid arthritis in the setting of active tuberculosis remain difficult.

A 64-year-old woman with a 10-year history of rheumatoid arthritis (functional class III and radiologic stage 3, according to Steinbrocker's criteria) had begun treatment with infliximab at a dose of 3 mg per . . . [Full Text of this Article]

This article has been cited by other articles:

• D'Haens, G. (2007). Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 [Full Text]